Mario Sznol, MD

Professor of Medicine (Medical Oncology); Co-Director, Cancer Immunology Program at Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

General Adult Urology

Urologic Oncology Program

Yale Cancer Center: Melanoma Program | Prostate & Urologic Cancers Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Internal Medicine AB of Internal Medicine (1985)

  • Medical Oncology AB of Internal Medicine (1987)

Clinical Trials

Conditions Study Title
Melanoma, skin A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma
Kidney A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Kidney, Other Urinary A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy
Lung, Melanoma, skin A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma
Kidney A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Melanoma, skin A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Bladder, Kidney, Lung, Melanoma, skin, Breast A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
Lung, Melanoma, skin Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Kidney, Melanoma, skin A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Kidney, Melanoma, skin A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Brain and Nervous System, Lung, Melanoma, skin A Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Melanoma, skin A Phase II, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Lung, Melanoma, skin MK-3475 in NSCLC Patients With Brain Metastases
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Kidney Active Surveillance of the Small Renal Mass

Edit this profile

Contact Info

Mario Sznol, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8

New Haven, CT 06511
View on map...
Mailing Address
Medical OncologyPO Box 208028
333 Cedar Street

New Haven, CT 06520-8028